Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Sponsor
Canadian Cancer Trials Group
Study ID
NCT03768570
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months

Study Details

The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after completion of surgery, chemotherapy and radiotherapy.

Key Dates

Start date
Oct 25, 2019
Status verified
May 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
82 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Surveillance
  • Active Comparator: Durvalumab

Primary Outcome Measure

Disease-free survival [ Time Frame: 5 years ]

Related Studies